An integrative review on current evidence of testosterone replacement therapy for the andropause

Maturitas

Volumn 45, Issue 1, 2003, Pages 15-27

  Tan, Robert S ^a   Culberson, John W ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Aging; Andropause; Testosterone

Indexed keywords

TESTOSTERONE;

AGING; ANDROPAUSE; BODY COMPOSITION; BONE DENSITY; BONE MASS; BRAIN FUNCTION; BREAST AUGMENTATION; BREAST CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; DIAGNOSTIC APPROACH ROUTE; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG SAFETY; EDEMA; ERYTHROCYTOSIS; GYNECOMASTIA; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; LONG TERM CARE; MALE; NONHUMAN; OBESITY; PROSTATE CANCER; RASH; REVIEW; SIDE EFFECT; SLEEP APNEA SYNDROME; TESTOSTERONE BLOOD LEVEL; TESTOSTERONE REPLACEMENT THERAPY; WASTING SYNDROME;

ANIMALIA;

EID: 0038513848     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(03)00083-5     Document Type: Review

References (64)

1. Tan R.S. The andropause mystery. 2001;AMRED Publishing, Houston.
2. Morales A., Heaton J.P., Carson C.C. III. Andropause: a misnomer for a true clinical entity. J. Urol. 163:(3):2000;705-712.
3. Chatterjee B., Roy A.K. Changes in hepatic androgen sensitivity and gene expression during aging. J. Steroid Biochem. Mol. Biol. 37:(3):1990;437-445.
4. Tan R.S., Philip P.S. Perceptions of and risk factors for andropause. Arch. Androl. 43:(2):1999;97-103.
5. Nahoul K., Roger M. Age-related decline of plasma bioavailable testosterone in adult men. J. Steroid Biochem. 35:(2):1990;293-299.
6. Morley J.E., Charlton E., Patrick E., et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism. 49:(9):2000;1239-1242.
7. Vermeulen A., Verdonck L., Kaufmann J.M. A critical evaluation of simple methods for the estimation of free testosterone in serum. J. Clin. Endocrinol. Metab. 86:(6):2001;2903.
8. Matsumoto A.M. Andropause: clinical implications of the decline in serum testosterone levels with aging in men. J. Gerontol. A Biol. Sci. Med. Sci. 57:(2):2002;M76-99.
9. IMS Sales Data, IMS Health, Inc., Westport, Conn, 2001.
10. Simerly R.B., Chang C., Muramatsu M., Swanson L.W. Distribution of androgen and estrogen receptor mRNA-containing cells in the brain: an in situ hybridization study. J. Comp. Neurol. 294:(1):1990;76-95.
11. Herve J, Pluciennik F, Verrecchia F, et al. Influence of molecular structure of steroids on their ability to interrupt gap junctional communication. J Membr Biol 1996;149(3):179-87.
12. Tobin V.A., Millar R.P., Canny B.J. Testosterone acts directly at the pituitary to regulate gonadotropin-releasing hormone-induced calcium signals in male rat gonadotropes. Endocrinology. 138:(8):1997;3314-3319.
13. Gandy S., Almeida O.P., Fonte J., et al. Chemical andropause and amyloid-beta peptide. J. Am. Med. Assoc. 285:(17):2001;2195-2196.
14. Papasozomenos S.C. Heat shock induces rapid dephosphorylation of tau in both female and male rats followed by hyperphosphorylation only in female rats: implications for Alzheimer's disease. J. Neurochem. 66:(3):1996;1140-1149.
15. Janowsky J.S., Oviatt S.K., Orwoll E.S. Testosterone influences spatial cognition in older men. Behav. Neurosci. 108:(2):1994;325-332.
16. Tan R.S., Pu S.J. The andropause and memory loss: is there a link between androgen decline and dementia in the aging male. Asian J. Androl. 3:(3):2001;169-174.
17. Cherrier M.M., Asthana S., Plymate S., et al. Testosterone supplementation improves spatial and verbal memory in healthy older men. Neurology. 57:(1):2001;80-88.
18. Van Goozen S.H., Cohen-Kettenis P.T., Gooren L.J., Frijda N.H., Van de Poll N.E. Gender differences in behaviour: activating effects of cross-sex hormones. Psychoneuroendocrinology. 20:(4):1995;343-363.
19. Sih R., Morley J.E., Kaiser F.E., Perry H.M. III, Patrick P., Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J. Clin. Endocrinol. Metab. 82:(6):1997;1661-1667.
20. Kaiser F.E., Viosca S.P., Morley J.E., Mooradian A.D., Davis S.S., Korenman S.G. Impotence and aging: clinical and hormonal factors. J. Am. Geriatr. Soc. 36:1988;511-519.
21. Lugg J.A., Rajfer J., Gonzalez-Cadavid N.F. Dihydrotestosterone is the active androgen in the maintenance of nitric oxide-mediated penile erection in the rat. Endocrinology. 136:(4):1995;1495-1501.
22. Hajjar R.R., Kaiser F.E., Morley J.E. Outcomes of long-term testosterone replacement in older hypogonadal males retrospective analysis. J. Clin. Endocrinol. Metab. 82:(11):1997;3793-3796.
23. Carani C., Granata A.R., Bancroft J., Marrama P. The effects of testosterone replacement on nocturnal penile tumescence and rigidity and erectile response to visual erotic stimuli in hypogonadal men. Psychoendocrinology. 20:(7):1995;743-753.
24. Jain P., Rademaker A.W., McVary K.T. Testosterone supplementation for erectile dysfunction: results of a meta-analysis. J. Urol. 164:(2):2000;371-375.
25. Hurley B.F., Seals D.R., Hagberg J.M., et al. High-density lipoprotein cholesterol in bodybuilders vs. powerlifters. Negative effects of androgen use. J. Am. Med. Assoc. 242:(4):1984;507-513.
26. Tenover J.S. Effects of testosterone supplementation in the aging male. J. Clin. Endocrinol. Metab. 75:(4):1992;1092-1098.
27. Snyder P.J., Peachey H., Hannoush P., et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J. Clin. Endocrinol. Metab. 84:(8):1999;2647-2653.
28. Morley J.E., Perry H.M. III, Kaiser F.E., et al. Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J. Am. Geriatr. Soc. 41:(2):1993;149-152.
29. Khaw K.T., Barrett-Connor E. Endogenous sex hormones, high-density lipoprotein cholesterol, and other lipoprotein fractions in men. Arterioscler. Thromb. 11:(3):1991;489-494.
30. Kenny A.m, Prestwood K.M., Gruman C.A., et al. Effects of transdermal testosterone on lipids and vascular reactivity in older men with low bioavailable testosterone levels. J. Gerontol. A Biol. Sci. Med. Sci. 57:(7):2002;460-465.
31. Jaffe M.D. Effect of testosterone cypionate on postexercise ST segment depression. Br. Heart J. 39:(11):1977;1217-1222.
32. Rosano G.M., Leonardo F., Pagnotta P., et al. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation. 99:(13):1999;1666-1670.
33. Webb C.M., McNeill J.G., Hayward C.S., de Zeigler D., Collins P. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation. 100:(16):1999;1690-1696.
34. Ong P.J., Patrizi G., Chong W.C., Webb C.M., Hayward C.S., Collins P. Testosterone enhances flow-mediated brachial artery reactivity in men with coronary artery disease. Am. J. Cardiol. 85:(2):2000;269-272.
35. Allison D.B., Zhu S.K., Plankey M., Faith M.S., Heo M. Differential associations of body mass index and adiposity with all-cause mortality among men in the first and second National Health and Nutrition Examination Surveys (NHANES I and NHANES II) follow-up studies. Int. J. Obes. Relat. Metab. Disord. 26:(3):2002;410-416.
36. Cohen P.G. Aromatase, adiposity, aging and disease. The hypogonadal-metabolic-atherogenic-disease and aging connection. Med. Hypotheses. 56:(6):2001;702-708.
37. Wang C., Swedloff R.S., Iranmanesh A., et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group. J. Clin. Endocrinol. Metab. 85:(8):2000;2839-2853.
38. Frontera W.R., Hughes V.A., Lutz K.J., Evans W.J. A cross-sectional study of muscle strength and mass in 45- to 78-year old men and women. J. Appl. Physiol. 71:1991;644-650.
39. Harris T. Muscle mass and strength: relation to function in population studies. J. Nutr. 127:(5Suppl.):1997;1004S-1006S.
40. Harris T. Muscle mass and strength: relation to function in population studies. J. Nutr. 127:(5Suppl.):1997;1004S-1006S.
41. Marin P. Androgen treatment of abdominally obese men. Obes. Res. 1:1993;245-251.
42. Kenny A.M., Prestwood K.M., Gruman C.A., Marcello K.M., Raisz L.G. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J. Gerontol. A Biol. Sci. Med. Sci. 56:(5):2001;M266-M272.
43. Bakhshi V., Elliot M., Gentili A., Godschalk M., Mulligan T. Testosterone improves rehabilitation outcomes in older men. J. Am. Geriatr. Soc. 45:(5):2000;550-553.
44. Grinspoon S.K., Donovan D.S. Jr, Bilezikian J.P. Aetiology and pathogenesis of hormonal and metabolic disorders in HIV infection. Baillieres Clin. Endocrinol. Metab. 8:(4):1994;35-55.
45. Greendale G.A., Kritz-Silverstein D., Seeman T., Barrett-Conner E. Higher basal cortisol predicts verbal memory loss in postmenopausal women. The Rancho Bernardo study. J. Am. Geriatr. Soc. 48:(12):2000;1655-1658.
46. Khosla S., Melton L.J. Jr, Atkinson E.J., O'Fallon W.M., Klee G.G., Riggs B.L. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J. Clin. Endocrinol. Metab. 83:(7):1998;2266-2274.
47. Colvard D.S., Eriksen E.F., Keeting P.E., et al. Identification of androgen receptors in normal human osteoblast-like cells. Proc. Natl. Acad. Sci. USA. 86:(3):1989;854-857.
48. Tan R.S., Pu S.J. Testosterone replacement in andropause as restorative therapy for older homebound males. Home Health Care Consul. 9:(2):2002;9-13.
49. Christmas C., O'Connor K.G., Harman S.M., et al. Growth hormone and sex steroid effects on bone metabolism and bone mineral density in healthy aged women and men. J. Gerontol. A Biol. Sci. Med. Sci. 57:(1):2002;12-18.
50. Bhasin S., Woodhouse L., Casaburi R., et al. Testosterone dose-response relationships in healthy young men. Am. J. Physiol. Endocrinol. Metab. 281:(6):2001;E1172-E1181.
51. Morgentaler A., Bruning C.O. III, DeWolf W.C. Occult prostate cancer in men with low serum testosterone levels. J. Am. Med. Assoc. 276:(23):1996;1904-1906.
52. Dobs A.S., Meikle A.W., Arver S., Sanders S.W., Caramelli K.E., Mazer N.A. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J. Clin. Endocrinol. Metab. 84:(10):1999;3469-3478.
53. Schneider BK, Pickett CK, Zwillich CW, McDermott MT, et al. Influence of testosterone on breathing during sleep, J Appl Physiol 1986; 61(2):618-23.
54. Anderson R.A., Wallace A.M., Wu F.C. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. II. Pharmacokinetics and pharmacodynamics of once weekly administration of testosterone enanthate. J. Clin. Endocrinol. Metab. 81:(3):1996;896-901.
55. Reddy P., White C.M., Dunn A.B., et al. The effect of testosterone on health-related quality of life in elderly males - a pilot study. J. Clin. Pharm. Ther. 25:2000;421-426.
56. Kenny A.M., Prestwood K.M., Raisz L.G. Short term effects of intramuscular and transdermal testosterone on bone turnover, prostate symptoms, cholesterol and hematocrit over age 70 with low testosterone levels. Endocr. Res. 26:(2):2000;153-168.
57. Bhasin S., Buckwalter J.G. Testosterone supplementation in older men: a rational idea whose time has not yet come. J. Androl. 22:(5):2001;718-731.
58. Cohen P.G. Aromatase, adiposity, aging and disease. The hypogonadal-metabolic-atherogenic-disease and aging connection. Med. Hypotheses. 56:(6):2001;702-708.
59. Volek J.S., Kraemer W.J., Bush J.A., Incledon T., Boetes M. Testosterone and cortisol in relationship to dietary nutrients and resistance exercise. J. Appl. Physiol. 82:(1):1997;49-54.
60. Stepto N.K., Carey A.L., Staudacher H.M., Cummings N.K., Burke L.M., Hawley J.A. Effect of short-term fat adaptation on high-intensity training. Med. Sci. Sports Exerc. 34:(3):2002;449-455.
61. Kraemer W.J., Hakkinen K., Newton R.U., et al. Effects of heavy-resistance training on hormonal response patterns in younger vs. older men. J. Appl. Physiol. 87:(3):1999;982-992.
62. Sundaram K., Kumar N. 7alpha-methyl-19-nortestosterone (MENT): the optimal androgen for male contraception and replacement therapy. Int. J. Androl. 23:(Suppl. 2):2000;13-15.
63. Endocrine Society, Andropause Consensus Statement, 2001.
64. Kunelius P., Lukkarinen O., Hannuksela M.L., Itkonen O., Tapanainen J.S. The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. J. Clin. Endocrinol. Metab. 87:(4):2002;1467-1472.